ClinicalTrials.gg
RecruitingNCT04790253PRIMALungUpdated Oct 16, 2026

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

An interventional study of Prophylactic cranial irradiation in Limited Stage Small Cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Recruiting at 55 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.
Updated Oct 16, 2026First site in NetherlandsNo longer in Germany+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Small Cell Lung Carcinoma with a site in France — 30 open to participants now, 53 under way, 17 of them phase 3. Small Cell Lung Carcinoma · France.

Planned enrollment
17th of 110
600 · median 198
Started
2022
with 7 others
No phase
5 of 120
2 open now
Primary completion
2028-04
later than 28 of 52 live
Registered
67th of 120
by date
Lead sponsor
4 of 120
European Organisation for Research and Treatment of Cancer - EORTC

Among the 120 studies in Small Cell Lung Carcinoma with a site in France, this one is the 17th largest by planned enrollment of the 110 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 with no phase, reaches primary completion later than 28 of the 52 other live ones, and was the 67th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

30 of the 120 studies in Small Cell Lung Carcinoma with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Small Cell Lung Carcinoma with a site in France, or all of them as a file.
02

Study summary

In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall survival compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the entire study population.

Read the detailed description

The primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall survival compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the entire study population under the treatment policy strategy.

The secondary objectives are:

  • To test with a one-sided type I error of 2.5% whether brain MRI surveillance is superior in terms of cognitive failure free survival (CFFS) compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the study population.
  • To test with a one-sided type I error of 2.5% whether brain MRI surveillance is superior in terms of global health status/QoL and cognitive functioning according to EORTC QLQ-C30 questionnaire compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the study population.
  • To evaluate the frequency and severity of toxicities according to CTCAE v5.0 in the two arms in the treated population (i.e. patients who have started treatment).

The exploratory objectives are:

  • To compare OS and CFFS between the arms within the subgroups of patients with LS and ES disease.
  • To compare OS and CFFS between the arms within the subgroups: HA-PCI or not, first-line immunotherapy or not, memantine or not.
  • To compare cognitive failure free survival (CFFS) rate at 12 months after randomization between the arms.
  • To compare the cumulative incidence of cognitive failures with death as a competing risk between the arms.
  • To compare brain-metastasis-free survival (BMFS) between the arms.
  • To compare progression free survival (PFS) between the arms.
  • To compare time to brain-metastasis-attributed death (TBMAD) between the arms.
  • To compare other QoL scales according to EORTC QLQ-C30 and QLQ-BN20 questionnaires between arms.
  • To evaluate the cost-effectiveness of MRI surveillance alone versus MRI surveillance combined with PCI.
  • To collect blood for biobanking.
03

Conditions studied

  • Limited Stage Small Cell Lung Cancer
  • Extensive-stage Small-cell Lung Cancer

Keywords

  • Prophylactic cerebral Irradiation
  • small cell lung cancer
  • PCI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Histologically/ proven diagnosis of SCLC
  • Limited and extensive stage
  • LS SCLC: Stage I-III (T any, N any, M0, according to UICC TNM staging v8.0) that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumour/nodal volume that is too large to be encompassed in a tolerable radiation plan.
  • ES SCLC: Stage IV (T any, N any, M 1a/b), or T3-4 due to multiple lung nodules that are too extensive or have tumour/nodal volume that is too large to be encompassed in a tolerable radiation plan.
  • Completed standard therapy prior to randomization:
  • For patients with LS-SCLC, this includes a combination of 4-6 cycles of platinum-based doublet chemotherapy and either definitive thoracic radiotherapy (including SBRT for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the treating physician, but is not mandated.
  • For patients with ES-SCLC, this includes 4-6 cycles of platinum-based doublet chemotherapy either with or without thoracic radiotherapy

    o Immunotherapy concurrent with and/or to standard therapy is allowed at the discretion of the treating physician.

  • Absence of progressive disease after completed standard therapy on systemic imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of Chest/Abdomen/Pelvis and brain MRI), 28 days before randomization.
  • Absence of or after completed standard therapy on systemic imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of Chest/Abdomen/Pelvis and brain MRI), within 28 days before randomization.
  • Interval from day 1 of last cycle of chemotherapy to randomization of ≤8 weeks
  • PS ≤ 2
  • Estimated ≥ 30 mL/min as calculated using the formula
  • Women of child bearing potential () must have a negative serum pregnancy test within 3 days prior to randomization.

Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e. females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antioestrogens, low body weight, ovarian suppression or other reasons.

  • Patients Women of childbearing / should use adequate measures, as defined by the investigator, during the entire period of the radiotherapy treatment study participation and for at least 30 days after the last dose of radiotherapy. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Such methods include:
  • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
  • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
  • Intrauterine device (IUD)
  • Intrauterine hormone-releasing system (IUS)
  • Bilateral tubal occlusion
  • Vasectomized partner
  • Sexual abstinence (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient)
  • Female subjects who are breast feeding should discontinue nursing prior to the first dose of radiotherapy and during the entire period of the radiotherapy treatmentuntil 30 days after the administration of the last dose of radiotherapy.
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Before patient registration/randomization, written must be given according to ICH/GCP, and national/local regulations.

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to the brain or whole brain radiotherapy. Note: Patients who have undergone prior stereotactic radiosurgery for benign tumours or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis. Discussion with EORTC Headquarters is mandatory, before the randomization.
  • Known to imaging tracer or any product of contrast media, such as allergy or insufficient renal function. Known contraindication to MRI, such as implanted metal devices or foreign bodies.
  • Other active hematologic or solid tumour requiring current active treatment.
  • Any unresolved toxicities from prior therapy (e.g., chemotherapy, radiotherapy) greater than grade 2 (according to CTCAE v5.0) at the time of randomization.
  • Patient with severe active comorbidities, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to randomization
  • Transmural myocardial infarction within 6 months prior to randomization
  • Acute infection requiring treatment at the time of randomization
  • exacerbation or other acute respiratory illness precluding study therapy at the time of randomization
  • Severe hepatic disease defined as a diagnosis of class B or C hepatic disease
  • positive with \< 200 cells/microliter. Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 16 weeks prior to randomization.
  • Any severe comorbidity that in the opinion of the Investigator might hamper the participation to the study and/or the treatment administration.
  • Severe neurological (including dementia and epilepsy) or psychiatric disorder requiring active treatment.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    PCI followed by brain MR surveillance

    Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain. Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months. Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician.

    Radiation: Prophylactic cranial irradiation

  • No intervention
    MRI Active Surveillance

    Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.

Interventions

  • RadiationProphylactic cranial irradiation

    Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.

06

What researchers measure

Primary outcomes

  1. Overall survival

    The primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall survival compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the entire study population

    Time frame: 12 Months

Secondary outcomes

  1. cognitive failure free survival

    To test with a one-sided type I error of 2.5% whether brain MRI surveillance is superior in terms of cognitive failure free survival (CFFS) compared to prophylactic cranial irradiation (PCI)

    Time frame: 12 Months

  2. Quality of Life

    To show that brain MRI surveillance is superior in terms of global health status/QoL and cognitive functioning according to EORTC QLQ-C30 questionnaire compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance

    Time frame: 12 Months

  3. Safety profiling

    To evaluate the frequency and severity of toxicities according to CTCAE v5.0 in the two arms in the treated population (i.e. patients who have started treatment).

    Time frame: 12 Months

07

Study locations

41 of 55 sites recruiting
  • Medical University of Graz - Radio-oncology
    Graz, 8036, Austria
    Recruiting
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
    Recruiting
  • AZ Groeninge Kortrijk - Campus Kennedylaan
    Kortrijk, 8500, Belgium
    Recruiting
  • C.H.U. Sart-Tilman
    Liège, 4000, Belgium
    Terminated

    Not enrolling at this site — choose another above.

  • Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus
    Wilrijk, 2610, Belgium
    Recruiting
  • Institut de Cancerologie de l Ouest (ICO) - Angers
    Angers, FR 49055, France
    Recruiting
  • Institut Sainte Catherine (UNICANCER)
    Avignon, 84918, France
    Recruiting
  • Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque (UNICANCER)
    Bayonne, 64100, France
    Recruiting
  • Institut Bergonie (UNICANCER)
    Bordeaux, 33067, France
    Recruiting
  • Centre Francois Baclesse (CLCC) (UNICANCER)
    Caen, 14076, France
    Recruiting
  • Centre Hospitalier Metropole Savoie
    Chambéry, FR 73000, France
    Recruiting
  • Centre Hospitaliler Cholet
    Cholet, FR 49325, France
    Recruiting
  • Centre Hopitalier Intercommunal De Creteil
    Créteil, FR 94010, France
    Recruiting
  • CHU de Dijon - Centre Georges-Francois-Leclerc (UNICANCER)
    Dijon, 21079, France
    Recruiting
  • Centre Hospitalier Departemental Vendee (UNICANCER)
    La Roche-sur-Yon, 85925, France
    Recruiting
  • Centre Oscar Lambret
    Lille, FR 59020, France
    Recruiting
  • Centre Hospitalier Bretagne Sud - Site du Scorff
    Lorient, FR 56322, France
    Recruiting
  • Institut Paoli-Calmettes (UNICANCER)
    Marseille, 13237, France
    Recruiting
  • Institut du Cancer de Montpellier (UNICANCER)
    Montpellier, 34298, France
    Recruiting
  • Assistance Publique Hopitaux Paris- APHP - APHP Sorbonne Univ - Hopital la Pitie-Salpetriere
    Paris, FR 75013, France
    Not yet recruiting
  • Institut Curie- Hopital de Paris
    Paris, FR 75248, France
    Not yet recruiting
  • Centre Catalan d'Oncologie (UNICANCER)
    Perpignan, 66000, France
    Recruiting
  • Centre Catalan d'Oncologie
    Perpignan, FR 66000, France
    Recruiting
  • CHU de Lyon - Hopital Lyon Sud (UNICANCER)
    Pierre-Bénite, 69495, France
    Recruiting
  • Centre Henri Becquerel (UNICANCER)
    Rouen, 76038, France
    Recruiting
  • Hospi Grand Ouest - Clinique Mutualiste de l'Estuaire
    Saint-Nazaire, FR 44600, France
    Not yet recruiting
  • CHU Saint-Etienne - Hopital Nord
    Saint-Priest-en-Jarez, FR 42270, France
    Not yet recruiting
  • Institut de Cancerologie Strasbourg Europe (UNICANCER)
    Strasbourg, 67200, France
    Recruiting
  • Polyclinique de l'Ormeau
    Tarbes, FR 65000, France
    Recruiting
  • Institut de Cancerologie de Lorraine
    Vandœuvre-lès-Nancy, FR 54519, France
    Recruiting
  • Centre d'Oncologie Saint-Yves
    Vannes, FR 56000, France
    Recruiting
  • Gustave Roussy (UNICANCER)
    Villejuif, 94805, France
    Recruiting
  • IRCCS Azienda Ospedaliera Universitaria San Martino "IST" - IRCCS - AUO San Martino - IST
    Genova, 16132, Italy
    Not yet recruiting
  • ULSS 9 Scaligera Veneto - Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital
    Legnago, 37045, Italy
    Not yet recruiting
  • Fondazione IRCCS - Policlinico San Matteo
    Pavia, 27100, Italy
    Not yet recruiting
  • ASST-Bergamo Ospedale Treviglio-Caravaggio
    Treviglio, 24047, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
    Verona, 37134, Italy
    Not yet recruiting
  • University Medical Center Groningen
    Groningen, NL 9713 GZ, Netherlands
    Not yet recruiting
  • Medical University Of Gdansk
    Gdansk, 80 211, Poland
    Recruiting
  • Regional Cancer Centre
    Olsztyn, 10 228, Poland
    Recruiting
  • Hospital Universitario Badajoz
    Badajoz, 06080, Spain
    Not yet recruiting
  • Hospital Insular De Gran Canaria
    Las Palmas de Gran Canaria, 35016, Spain
    Not yet recruiting
  • Hospital Universitario Puerta De Hierro
    Majadahonda, 28222, Spain
    Recruiting
  • Inselspital
    Bern, 3010, Switzerland
    Recruiting
  • Reseau Hospitalier Neuchatelois - RHNe - La Chaux de Fonds
    La Chaux-de-Fonds, 2303, Switzerland
    Recruiting
  • Kantonsspital St Gallen
    Sankt Gallen, 9007, Switzerland
    Recruiting
  • UniversitaetsSpital Zurich
    Zurich, 8091, Switzerland
    Recruiting
  • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre
    Bristol, BS2 8ED, United Kingdom
    Recruiting
  • NHS Lothian - Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
    Not yet recruiting
  • Maidstone & Tunbridge Wells NHS Trust - Maidstone Hospital
    Maidstone, ME16 9QQ, United Kingdom
    Recruiting
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
    Recruiting
  • Nottingham University Hospitals NHS Trust - City Hospital
    Nottingham, NG5 1PB, United Kingdom
    Recruiting
  • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
    Sheffield, S10 2SJ, United Kingdom
    Recruiting
  • Royal Marsden Hospital - Sutton
    Sutton, SM2 5PT, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Apr 2028, 66 months after the start.

Of 45 non-industry interventional studies with no phase under Small Cell Lung Carcinoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 73. This study's planned 66 months is above that.

Counting every sponsor, half of 47 studies reached it within 52 months; a quarter within 25 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 10, 2021
StartActual
Oct 27, 2022
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
20 sites added, 6 sites removed — first site in Netherlands; no longer in Germany. 4 sites changed recruiting status (3 now recruiting, 1 now terminated)
Show 4 sites
  • C.H.U. Sart-Tilman · Liège, BelgiumRecruiting→Terminated
  • Institut Paoli-Calmettes (UNICANCER) · Marseille, FranceNot yet recruiting→Recruiting
  • Maidstone & Tunbridge Wells NHS Trust - Maidstone Hospital · Maidstone, United KingdomNot yet recruiting→Recruiting
  • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital · Sheffield, United KingdomNot yet recruiting→Recruiting
Show 20 added (15 France, 2 Switzerland, 1 Netherlands, 1 Poland, 1 Spain)
  • Institut de Cancerologie de l Ouest (ICO) - Angers · Angers, France
  • Centre Hospitalier Metropole Savoie · Chambéry, France
  • Centre Hospitaliler Cholet · Cholet, France
  • Centre Hopitalier Intercommunal De Creteil · Créteil, France
  • Centre Oscar Lambret · Lille, France
  • Centre Hospitalier Bretagne Sud - Site du Scorff · Lorient, France
  • Assistance Publique Hopitaux Paris- APHP - APHP Sorbonne Univ - Hopital la Pitie-Salpetriere · Paris, France
  • Institut Curie- Hopital de Paris · Paris, France
  • Centre Catalan d'Oncologie · Perpignan, France
  • CHU de Lyon - Hopital Lyon Sud (UNICANCER) · Pierre-Bénite, France
  • Hospi Grand Ouest - Clinique Mutualiste de l'Estuaire · Saint-Nazaire, France
  • CHU Saint-Etienne - Hopital Nord · Saint-Priest-en-Jarez, France
  • Polyclinique de l'Ormeau · Tarbes, France
  • Institut de Cancerologie de Lorraine · Vandœuvre-lès-Nancy, France
  • Centre d'Oncologie Saint-Yves · Vannes, France
  • University Medical Center Groningen · Groningen, Netherlands
  • Medical University Of Gdansk · Gdansk, Poland
  • Hospital Insular De Gran Canaria · Las Palmas de Gran Canaria, Spain
  • Kantonsspital St Gallen · Sankt Gallen, Switzerland
  • UniversitaetsSpital Zurich · Zurich, Switzerland
Show 6 removed
  • CHU de Lyon - Hopital Lyon Sud (UNICANCER) · Pierre Benite Cedex, France
  • Universitaetsklinikum Aachen AOR - Medizinische Fakultaet der RWTH · Aachen, Germany
  • Medical University Of Gdansk · Gdańsk, Poland
  • Hospital Insular De Gran Canaria · Las Palmas De Gran Canaria, Spain
  • Kantonsspital St Gallen · Saint Gallen, Switzerland
  • UniversitaetsSpital Zurich · Zürich, Switzerland
Oct 16, 2026
Site contacts
Changed at 35 sites. See the sites
Show 35 sites
  • Medical University of Graz - Radio-oncology · Graz, AustriaContact removed (no phone or email listed)
  • Institut Jules Bordet · Anderlecht, BelgiumContact removed (no phone or email listed)
  • Universitair Ziekenhuis Antwerpen · Edegem, BelgiumContact removed (no phone or email listed)
  • AZ Groeninge Kortrijk - Campus Kennedylaan · Kortrijk, BelgiumContact removed (no phone or email listed)
  • C.H.U. Sart-Tilman · Liège, BelgiumContact removed (no phone or email listed)
  • Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus · Wilrijk, BelgiumContact removed (no phone or email listed)
  • Institut Sainte Catherine (UNICANCER) · Avignon, FranceContact removed (no phone or email listed)
  • Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque (UNICANCER) · Bayonne, FranceContact removed (no phone or email listed)
  • Institut Bergonie (UNICANCER) · Bordeaux, FranceContact removed (no phone or email listed)
  • Centre Francois Baclesse (CLCC) (UNICANCER) · Caen, FranceContact removed (no phone or email listed)
  • CHU de Dijon - Centre Georges-Francois-Leclerc (UNICANCER) · Dijon, FranceContact removed (no phone or email listed)
  • Centre Hospitalier Departemental Vendee (UNICANCER) · La Roche-sur-Yon, FranceContact removed (no phone or email listed)
  • Institut Paoli-Calmettes (UNICANCER) · Marseille, FranceContact removed (no phone or email listed)
  • Institut du Cancer de Montpellier (UNICANCER) · Montpellier, FranceContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Centre Catalan d'Oncologie (UNICANCER) · Perpignan, FranceContact removed (no phone or email listed)
  • Centre Henri Becquerel (UNICANCER) · Rouen, FranceContact removed (no phone or email listed)
  • Institut de Cancerologie Strasbourg Europe (UNICANCER) · Strasbourg, FranceContact removed (no phone or email listed)
  • Gustave Roussy (UNICANCER) · Villejuif, FranceContact removed (no phone or email listed)
  • IRCCS Azienda Ospedaliera Universitaria San Martino "IST" - IRCCS - AUO San Martino - IST · Genova, ItalyContact removed (no phone or email listed)
  • ULSS 9 Scaligera Veneto - Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital · Legnago, ItalyContact removed (no phone or email listed)
  • Fondazione IRCCS - Policlinico San Matteo · Pavia, ItalyContact removed (no phone or email listed)
  • ASST-Bergamo Ospedale Treviglio-Caravaggio · Treviglio, ItalyContact removed (no phone or email listed)
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma · Verona, ItalyContact removed (no phone or email listed)
  • Regional Cancer Centre · Olsztyn, PolandContact removed (no phone or email listed)
  • Hospital Universitario Badajoz · Badajoz, SpainContact removed (no phone or email listed)
  • Hospital Universitario Puerta De Hierro · Majadahonda, SpainContact removed (no phone or email listed)
  • Inselspital · Bern, SwitzerlandContact removed (no phone or email listed)
  • Reseau Hospitalier Neuchatelois - RHNe - La Chaux de Fonds · La Chaux-de-Fonds, SwitzerlandContact removed (no phone or email listed)
  • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre · Bristol, United KingdomContact removed (no phone or email listed)
  • NHS Lothian - Western General Hospital · Edinburgh, United KingdomContact removed (no phone or email listed)
  • …and 5 more sites
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    20 sites added, 6 sites removed — first site in Netherlands; no longer in Germany. 4 sites changed recruiting status (3 now recruiting, 1 now terminated)
    Show 4 sites
    • C.H.U. Sart-Tilman · Liège, BelgiumRecruiting→Terminated
    • Institut Paoli-Calmettes (UNICANCER) · Marseille, FranceNot yet recruiting→Recruiting
    • Maidstone & Tunbridge Wells NHS Trust - Maidstone Hospital · Maidstone, United KingdomNot yet recruiting→Recruiting
    • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital · Sheffield, United KingdomNot yet recruiting→Recruiting
    Show 20 added (15 France, 2 Switzerland, 1 Netherlands, 1 Poland, 1 Spain)
    • Institut de Cancerologie de l Ouest (ICO) - Angers · Angers, France
    • Centre Hospitalier Metropole Savoie · Chambéry, France
    • Centre Hospitaliler Cholet · Cholet, France
    • Centre Hopitalier Intercommunal De Creteil · Créteil, France
    • Centre Oscar Lambret · Lille, France
    • Centre Hospitalier Bretagne Sud - Site du Scorff · Lorient, France
    • Assistance Publique Hopitaux Paris- APHP - APHP Sorbonne Univ - Hopital la Pitie-Salpetriere · Paris, France
    • Institut Curie- Hopital de Paris · Paris, France
    • Centre Catalan d'Oncologie · Perpignan, France
    • CHU de Lyon - Hopital Lyon Sud (UNICANCER) · Pierre-Bénite, France
    • Hospi Grand Ouest - Clinique Mutualiste de l'Estuaire · Saint-Nazaire, France
    • CHU Saint-Etienne - Hopital Nord · Saint-Priest-en-Jarez, France
    • Polyclinique de l'Ormeau · Tarbes, France
    • Institut de Cancerologie de Lorraine · Vandœuvre-lès-Nancy, France
    • Centre d'Oncologie Saint-Yves · Vannes, France
    • University Medical Center Groningen · Groningen, Netherlands
    • Medical University Of Gdansk · Gdansk, Poland
    • Hospital Insular De Gran Canaria · Las Palmas de Gran Canaria, Spain
    • Kantonsspital St Gallen · Sankt Gallen, Switzerland
    • UniversitaetsSpital Zurich · Zurich, Switzerland
    Show 6 removed
    • CHU de Lyon - Hopital Lyon Sud (UNICANCER) · Pierre Benite Cedex, France
    • Universitaetsklinikum Aachen AOR - Medizinische Fakultaet der RWTH · Aachen, Germany
    • Medical University Of Gdansk · Gdańsk, Poland
    • Hospital Insular De Gran Canaria · Las Palmas De Gran Canaria, Spain
    • Kantonsspital St Gallen · Saint Gallen, Switzerland
    • UniversitaetsSpital Zurich · Zürich, Switzerland
    Site contacts Changed at 35 sites. See the sites
    Show 35 sites
    • Medical University of Graz - Radio-oncology · Graz, AustriaContact removed (no phone or email listed)
    • Institut Jules Bordet · Anderlecht, BelgiumContact removed (no phone or email listed)
    • Universitair Ziekenhuis Antwerpen · Edegem, BelgiumContact removed (no phone or email listed)
    • AZ Groeninge Kortrijk - Campus Kennedylaan · Kortrijk, BelgiumContact removed (no phone or email listed)
    • C.H.U. Sart-Tilman · Liège, BelgiumContact removed (no phone or email listed)
    • Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus · Wilrijk, BelgiumContact removed (no phone or email listed)
    • Institut Sainte Catherine (UNICANCER) · Avignon, FranceContact removed (no phone or email listed)
    • Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque (UNICANCER) · Bayonne, FranceContact removed (no phone or email listed)
    • Institut Bergonie (UNICANCER) · Bordeaux, FranceContact removed (no phone or email listed)
    • Centre Francois Baclesse (CLCC) (UNICANCER) · Caen, FranceContact removed (no phone or email listed)
    • CHU de Dijon - Centre Georges-Francois-Leclerc (UNICANCER) · Dijon, FranceContact removed (no phone or email listed)
    • Centre Hospitalier Departemental Vendee (UNICANCER) · La Roche-sur-Yon, FranceContact removed (no phone or email listed)
    • Institut Paoli-Calmettes (UNICANCER) · Marseille, FranceContact removed (no phone or email listed)
    • Institut du Cancer de Montpellier (UNICANCER) · Montpellier, FranceContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Centre Catalan d'Oncologie (UNICANCER) · Perpignan, FranceContact removed (no phone or email listed)
    • Centre Henri Becquerel (UNICANCER) · Rouen, FranceContact removed (no phone or email listed)
    • Institut de Cancerologie Strasbourg Europe (UNICANCER) · Strasbourg, FranceContact removed (no phone or email listed)
    • Gustave Roussy (UNICANCER) · Villejuif, FranceContact removed (no phone or email listed)
    • IRCCS Azienda Ospedaliera Universitaria San Martino "IST" - IRCCS - AUO San Martino - IST · Genova, ItalyContact removed (no phone or email listed)
    • ULSS 9 Scaligera Veneto - Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital · Legnago, ItalyContact removed (no phone or email listed)
    • Fondazione IRCCS - Policlinico San Matteo · Pavia, ItalyContact removed (no phone or email listed)
    • ASST-Bergamo Ospedale Treviglio-Caravaggio · Treviglio, ItalyContact removed (no phone or email listed)
    • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma · Verona, ItalyContact removed (no phone or email listed)
    • Regional Cancer Centre · Olsztyn, PolandContact removed (no phone or email listed)
    • Hospital Universitario Badajoz · Badajoz, SpainContact removed (no phone or email listed)
    • Hospital Universitario Puerta De Hierro · Majadahonda, SpainContact removed (no phone or email listed)
    • Inselspital · Bern, SwitzerlandContact removed (no phone or email listed)
    • Reseau Hospitalier Neuchatelois - RHNe - La Chaux de Fonds · La Chaux-de-Fonds, SwitzerlandContact removed (no phone or email listed)
    • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre · Bristol, United KingdomContact removed (no phone or email listed)
    • NHS Lothian - Western General Hospital · Edinburgh, United KingdomContact removed (no phone or email listed)
    • …and 5 more sites
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04790253
Collaborators
UNICANCER
Responsible party
Sponsor
First posted
Mar 10, 2021
Start date
Oct 27, 2022
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

EORTC Reception
Contact
eortc@eortc.org
+3227741611
Corinne Faivre-Finn, MD
principal investigator · The Christie NHS Foundation Trust
Antonin Levy, MD
principal investigator · Centre Gustave Roussy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion